Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion
LLY•Eli Lilly signed an oncology research collaboration and licensing agreement with privately held Stipple Bio worth up to $5.9 billion. Stipple will receive an upfront payment, an equity investment, milestone payments and tiered royalties if resulting therapies reach the market.
1. Cancer research collaboration
Stipple Bio said it will use its Pointillist discovery platform to identify cancer-specific molecules, which Lilly will use to develop cancer therapies. The agreement includes an upfront payment, an equity investment from Lilly, and up to $5.9 billion in aggregate research, development and commercial milestone payments, plus tiered royalties on product sales if any therapies reach the market.




